Anzeige
Mehr »
Login
Samstag, 21.09.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Spark Energy Minerals - das beste Lithium-Investment aller Zeiten?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
401 Leser
Artikel bewerten:
(2)

Velico Medical, Inc: Velico Medical launches Blood Center Education Program with South Texas Blood & Tissue

BOSTON, Oct. 20, 2023 /PRNewswire/ -- Velico Medical is proud to announce the launch of its Blood Center Education Program (BCEP) at South Texas Blood & Tissue (STB&T), a subsidiary of San Antonio non-profit BioBridge Global.

"This collaboration is the first of its kind in the nation and reflects the shared vision of Velico and STB&T of advancing life-saving blood products through the development process," says Richard Meehan, President and CEO of Velico.

Velico's BCEP is designed to generate deep customer feedback on the commissioning and operational aspects of the FrontlineODP system for spray drying plasma.

FrontlineODP is expected to be an easy to produce, easy to use, point-of-care plasma product for transfusion in settings where current plasma products (most often frozen) are unavailable or inconvenient to use because of challenging cold chain logistics and short dating. Velico's proprietary spray drying process results in a powdered plasma product that can be stored in a refrigerator or at ambient temperature and then reconstituted on-scene in minutes. With FrontlineODP, plasma could become more readily available to first responders such as ground or air ambulances, in rural hospitals where plasma is typically not stocked,for the military, and during mass casualty events.

"South Texas Blood & Tissue is pleased to collaborate with Velico as a BCEP partner. We take great pride in our history of firsts, leading change and innovation in blood transfusion products and services," says Adrienne Mendoza, STB&T Chief Operating Officer.

Velico's development program has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00059.

About Velico:

Velico Medical, Inc. is a private US medical technology company, committed to the mission of eliminating preventable death from bleeding. Headquartered in Beverly, Massachusetts, USA. Velico personnel have substantial expertise and experience in transfusion medicine and medical device development. In support of its mission, Velico is developing partnerships with civilian, government and military blood center leadership, trauma surgeons, emergency medical physicians, military medics and first responders worldwide.

About South Texas Blood & Tissue: South Texas Blood & Tissue (STB&T) is a non-profit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties. It is the largest blood supplier in our region. In addition, STB&T supports the development of advanced therapies, including those derived from donated human cells and tissues used in research and in new therapies and cures for cancers and degenerative diseases. Through the generous life-legacy gifts of human tissue, STB&T also supports development of tissue allografts for patients in need of reconstructive surgery, repair or tissue regeneration. STB&T has a 47-year history serving the South Texas community and is part of the BioBridge Global family of non-profit organizations, which offers services in regenerative medicine and research including blood banking and resource management; cellular therapy; umbilical cord blood collection and storage; donated human tissue recovery and distribution for transplant; and testing of blood and plasma products to help patients in the United States and worldwide. STB&T has eight donor centers in South Texas and conducts hundreds of mobile blood drives each year. STB&T is online at SouthTexasBlood.org.

South Texas Blood & Tissue Joins Velico's Blood Centre Education Programme. L-R Bill Skillman, VP Commercial & Business Development, Velico, Audra Taylor, Executive Director, Blood Operations, Adrienne Blevins Mendoza, Chief Operating Officer, STB&T and SVP, BioBridge Global Harry D. Irizarry, Vice President of Sales and Bill Merritt, COO, Velico


Video - https://mma.prnewswire.com/media/2251183/velico_STBT_video.mp4

Photo - https://mma.prnewswire.com/media/2251182/Velico_Medical__Blood_Centre_Education_Programme.jpg

Logo - https://mma.prnewswire.com/media/2152986/Velico_Medical_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/velico-medical-launches-blood-center-education-program-with-south-texas-blood--tissue-301963401.html

© 2023 PR Newswire
Sondersituation: Vervielfachungschance bei diesen Goldaktien

Der Goldpreis haussiert und schwingt sich von Hoch zu Hoch. Getrieben von geopolitischen Unsicherheiten sowie der Aussicht auf eine lockere Geldpolitik der FED gehen Experten aktuell von weiter steigenden Notierungen bis sogar in den Bereich von 3.000 US-Dollar je Unze Gold aus.

Im Schatten des Basispreises notieren Goldproduzenten aus der zweiten Reihe sowie Explorationsunternehmen noch weit weg von ihren historischen Höchstständen entfernt und bieten dadurch erhebliches Aufholpotential.

In diesem kostenlosen Report geben wir Ihnen Favoriten an die Hand, die aufgrund von Sondersituation die Chance auf eine Kursvervielfachung besitzen.

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von dem weiter steigenden Kurs des Edelmetalls.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.